Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Die Radiologie
Erschienen in: Die Radiologie 5/2019

08.04.2019 | Allergien und Intoleranzreaktionen | Leitthema

Gadoliniumablagerungen – Morbus Gadolinium

verfasst von: P. Raczeck, P. Fries, A. Bücker, G. Schneider

Erschienen in: Die Radiologie | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Gadolinium(Gd)-haltige Kontrastmittel (KM) werden seit 1988 in der klinischen MRT-Routinediagnostik weltweit eingesetzt. Dabei wurden alle in der Routine verwendeten Kontrastmittel in der zugelassenen Dosierung hinsichtlich Verträglichkeit, Nebenwirkungsprofil und diagnostischer Wirksamkeit lange Zeit als sicher eingestuft. Mit der Beobachtung der nephrogenen systemischen Fibrose (NSF) und der Gd-Retention im Gehirn änderte sich diese Ansicht jedoch und führte in Europa zum Entzug bzw. zur Einschränkung der Zulassung linearer Gd-Chelate. Insbesondere die NSF sowie die akute Unverträglichkeitsreaktion sind bei der Betrachtung Gd-haltiger Kontrastmittel von primärer klinischer Relevanz. Die schon seit Langem in der Literatur beschriebenen Ablagerungen von gadoliniumhaltigen Strukturen bzw. Strukturkomplexen im Körper wurden in den letzten Jahren insbesondere durch Veröffentlichungen von Ablagerungen im Gehirn sowie auch im Knochenmark wieder in den Vordergrund gerückt, jedoch wurde bisher keine klinische Beschwerdesymptomatik und keine nachhaltige Konsequenz für die Gesundheit der Patienten hierdurch beobachtet. Als Morbus Gadolinium wird ein von überwiegend online aktiven Patienten(interessens)gruppen gebildeter, wissenschaftlich nicht sicher belegter Symptomkomplex beschrieben, der sich nach Anwendung von gadoliniumhaltigen Kontrastmitteln mit großem Beschwerdespektrum offenbart. Die Betroffenen sind von teils chronisch persistierenden, teils remittierenden, und nicht durch andere (Vor‑)Erkrankungen zu erklärenden Beschwerden geplagt.
Literatur
1.
Hao D, Ai T, Goerner F, Hu X, Runge VM, Tweedle M (2012) MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging 36(5):1060–1071PubMedCrossRef
2.
Bleicher AG, Kanal E (2008) Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine. Ajr Am J Roentgenol 191(6):W307–W311PubMedCrossRef
3.
4.
Kanal E, Tweedle MF (2015) Residual or retained gadolinium: practical implications for radiologists and our patients. Radiology 275(3):630–634PubMedCrossRef
5.
Grobner T (2006) Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21(4):1104–1108PubMedCrossRef
6.
Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17(9):2359–2362PubMedCrossRef
7.
Hope TA, High WA, Leboit PE, Chaopathomkul B, Rogut VS, Herfkens RJ, Brasch RC (2009) Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. Radiology 253(2):390–398PubMedCrossRef
8.
Wertman R, Altun E, Martin DR, Mitchell DG, Leyendecker JR, O’Malley RB, Parsons DJ, Fuller ER III, Semelka RC (2008) Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 248(3):799–806PubMedCrossRef
9.
Fretellier N, Idee JM, Guerret S, Hollenbeck C, Hartmann D, Gonzalez W, Robic C, Port M, Corot C (2011) Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest Radiol 46(2):85–93PubMedCrossRef
10.
Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J (2009) Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology 253(1):81–89PubMedCrossRef
11.
Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER III, Semelka RC (2009) Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy—report from two U.S. universities. Radiology 253(3):689–696PubMedCrossRef
12.
Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D (2014) High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 270(3):834–841PubMedCrossRef
13.
Murata N, Gonzalez-Cuyar LF, Murata K, Fligner C, Dills R, Hippe D, Maravilla KR (2016) Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and Bone tissue: preliminary results from 9 patients with normal renal function. Invest Radiol 51(7):447–453PubMedCrossRef
14.
Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku J, Haruyama T, Kitajima K, Furui S (2015) Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 276(1):228–232PubMedCrossRef
15.
McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR, Williamson EE, Eckel LJ (2015) Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 275(3):772–782PubMedCrossRef
16.
Joffe P, Thomsen HS, Meusel M (1998) Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5(7):491–502PubMedCrossRef
17.
Gibby WA, Gibby KA, Gibby WA (2004) Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol 39(3):138–142PubMedCrossRef
18.
Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, Ellen CM, Hauschka PV, Hannigan RE (2009) Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics 1(6):479–488PubMedCrossRef
19.
Runge VM (2000) Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging 12(2):205–213PubMedCrossRef
20.
Weiss KL (1990) Severe anaphylactoid reaction after i.v. Gd-DTPA. Magn Reson Imaging 8(6):817–818PubMedCrossRef
21.
Beaudouin E, Kanny G, Blanloeil Y, Guilloux L, Renaudin JM, Moneret-Vautrin DA (2003) Anaphylactic shock induced by gadoterate meglumine (DOTAREM). Eur Ann Allergy Clin Immunol 35(10):382–385PubMed
22.
Runge VM (2001) Safety of magnetic resonance contrast media. Top Magn Reson Imaging 12(4):309–314PubMedCrossRef
23.
Ansell G, Tweedie MC, West CR, Evans P, Couch L (1980) The current status of reactions to intravenous contrast media. Invest Radiol 15(6 Suppl):32–39CrossRef
24.
Jung JW, Kang HR, Kim MH, Lee W, Min KU, Han MH, Cho SH (2012) Immediate hypersensitivity reaction to gadolinium-based MR contrast media. Radiology 264(2):414–422PubMedCrossRef
25.
Kanal E, Maravilla K, Rowley HA (2014) Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence. Ajnr Am J Neuroradiol 35(12):2215–2226PubMedCrossRefPubMedCentral
26.
Semelka RC, Ramalho M, AlObaidy M, Ramalho J (2016) Gadolinium in humans: a family of disorders. Ajr Am J Roentgenol 207(2):229–233PubMedCrossRef
27.
ESUR Contrast Media Safety Committee (2018) ESUR Contrast Media guidelines version 10.0
28.
American College of Radiology (ACR), Committee on Drugs and Contrast Media (2017) ACR manual on contrast media. American College of Radiology, (version 10.3)
29.
Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, Leboit PE (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356(9234):1000–1001PubMedCrossRef
30.
Broome DR (2008) Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 66(2):230–234PubMedCrossRef
31.
Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA (2007) Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Ajr Am J Roentgenol 188(2):586–592PubMedCrossRef
32.
Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243(1):148–157PubMedCrossRef
33.
Shabana WM, Cohan RH, Ellis JH, Hussain HK, Francis IR, Su LD, Mukherji SK, Swartz RD (2008) Nephrogenic systemic fibrosis: a report of 29 cases. Ajr Am J Roentgenol 190(3):736–741PubMedCrossRef
34.
Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M, Guarner J, Pollack B, Saab G, Patel PR (2008) Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis 51(6):966–975PubMedCrossRef
35.
Nandwana SB, Moreno CC, Osipow MT, Sekhar A, Cox KL (2015) Gadobenate Dimeglumine administration and Nephrogenic systemic fibrosis: is there a real risk in patients with impaired renal function? Radiology 276(3):741–747PubMedCrossRef
36.
Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P (2008) Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 158(2):273–280PubMedCrossRef
37.
Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, Simpson K, Roditi GH (2007) Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 245(1):168–175PubMedCrossRef
38.
Rosenkranz AR, Grobner T, Mayer GJ (2007) Conventional or Gadolinium containing contrast media: the choice between acute renal failure or Nephrogenic Systemic Fibrosis? Wien Klin Wochenschr 119(9–10):271–275PubMedCrossRef
39.
Sanyal S, Marckmann P, Scherer S, Abraham JL (2011) Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis—an autopsy-based review. Nephrol Dial Transplant 26(11):3616–3626PubMedCrossRef
40.
Christensen KN, Lee CU, Hanley MM, Leung N, Moyer TP, Pittelkow MR (2011) Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 64(1):91–96PubMedCrossRef
41.
Rocklage SM, Worah D, Kim SH (1991) Metal ion release from paramagnetic chelates: what is tolerable? Magn Reson Med 22(2):216–221PubMedCrossRef
42.
Tweedle MF (1992) Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 27(Suppl 1):2–6
43.
Xia D, Davis RL, Crawford JA, Abraham JL (2010) Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X‑ray spectroscopy. Acta Radiol 51(10):1126–1136PubMedCrossRef
44.
Errante Y, Cirimele V, Mallio CA, Di L. V, Zobel BB, Quattrocchi CC (2014) Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol 49(10):685–690PubMedCrossRef
45.
Quattrocchi CC, Mallio CA, Errante Y, Beomonte ZB (2015) High T1 signal intensity in dentate nucleus after multiple injections of linear gadolinium chelates. Radiology 276(2):616–617PubMedCrossRef
46.
Quattrocchi CC, Mallio CA, Errante Y, Cirimele V, Carideo L, Ax A, Zobel BB (2015) Gadodiamide and dentate nucleus T1 Hyperintensity in patients with Meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol 50(7):470–472PubMedCrossRef
47.
Cao Y, Huang DQ, Shih G, Prince MR (2016) Signal change in the dentate nucleus on T1-weighted MR images after multiple administrations of Gadopentetate Dimeglumine versus Gadobutrol. Ajr Am J Roentgenol 206(2):414–419PubMedCrossRef
48.
Kanda T, Osawa M, Oba H, Toyoda K, Kotoku J, Haruyama T, Takeshita K, Furui S (2015) High signal intensity in dentate nucleus on Unenhanced T1-weighted MR images: association with linear versus Macrocyclic gadolinium chelate administration. Radiology 275(3):803–809PubMedCrossRef
49.
Weberling LD, Kieslich PJ, Kickingereder P, Wick W, Bendszus M, Schlemmer HP, Radbruch A (2015) Increased signal intensity in the dentate nucleus on Unenhanced T1-weighted images after Gadobenate Dimeglumine administration. Invest Radiol 50(11):743–748PubMedCrossRef
50.
Radbruch A, Weberling LD, Kieslich PJ, Hepp J, Kickingereder P, Wick W, Schlemmer HP, Bendszus M (2015) High-signal intensity in the dentate nucleus and Globus Pallidus on Unenhanced T1-weighted images: evaluation of the Macrocyclic gadolinium-based contrast agent Gadobutrol. Invest Radiol 50(12):805–810PubMedCrossRef
51.
Radbruch A, Weberling LD, Kieslich PJ, Hepp J, Kickingereder P, Wick W, Schlemmer HP, Bendszus M (2016) Intraindividual analysis of signal intensity changes in the dentate nucleus after consecutive serial applications of linear and Macrocyclic gadolinium-based contrast agents. Invest Radiol 51(11):683–690PubMedCrossRef
52.
Stojanov DA, Aracki-Trenkic A, Vojinovic S, Benedeto-Stojanov D, Ljubisavljevic S (2016) Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol 26(3):807–815PubMedCrossRef
53.
Schneider GK, Stroeder J, Roditi G, Colosimo C, Armstrong P, Martucci M, Buecker A, Raczeck P (2017) T1 signal measurements in pediatric brain: findings after multiple exposures to Gadobenate Dimeglumine for imaging of Nonneurologic disease. Ajnr Am J Neuroradiol 38(9):1799–1806PubMedCrossRefPubMedCentral
54.
Bjornerud A, Vatnehol SAS, Larsson C, Due-Tonnessen P, Hol PK, Groote IR (2017) Signal enhancement of the dentate nucleus at Unenhanced MR imaging after very high cumulative doses of the Macrocyclic gadolinium-based contrast agent Gadobutrol: an observational study. Radiology 285(2):434–444PubMedCrossRef
55.
Ramalho J, Castillo M, AlObaidy M, Nunes RH, Ramalho M, Dale BM, Semelka RC (2015) High signal intensity in Globus Pallidus and dentate nucleus on Unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology 276(3):836–844PubMedCrossRef
56.
Dekkers IA, Roos R, van der Molen AJ (2018) Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European Medicines Agency. Eur Radiol 28(4):1579–1584PubMedCrossRef
57.
Prosch H, Grois N, Wnorowski M, Steiner M, Prayer D (2007) Long-term MR imaging course of neurodegenerative Langerhans cell histiocytosis. Ajnr Am J Neuroradiol 28(6):1022–1028PubMedCrossRefPubMedCentral
58.
Maeda H, Sato M, Yoshikawa A, Kimura M, Sonomura T, Terada M, Kishi K (1997) Brain MR imaging in patients with hepatic cirrhosis: relationship between high intensity signal in basal ganglia on T1-weighted images and elemental concentrations in brain. Neuroradiology 39(8):546–550PubMedCrossRef
59.
Mochizuki H, Kamakura K, Masaki T, Okano M, Nagata N, Inui A, Fujisawa T, Kaji T (1997) Atypical MRI features of Wilson’s disease: high signal in globus pallidus on T1-weighted images. Neuroradiology 39(3):171–174PubMedCrossRef
60.
Frenzel T, Apte C, Jost G, Schockel L, Lohrke J, Pietsch H (2017) Quantification and assessment of the chemical form of residual gadolinium in the brain after repeated administration of gadolinium-based contrast agents: comparative study in rats. Invest Radiol 52(7):396–404PubMedPubMedCentralCrossRef
61.
Murata N, Murata K, Gonzalez-Cuyar LF, Maravilla KR (2016) Gadolinium tissue deposition in brain and bone. Magn Reson Imaging 34(10):1359–1365PubMedCrossRef
62.
Maximova N, Gregori M, Zennaro F, Sonzogni A, Simeone R, Zanon D (2016) Hepatic gadolinium deposition and reversibility after contrast agent-enhanced MR imaging of pediatric Hematopoietic stem cell transplant recipients. Radiology 281(2):418–426PubMedCrossRef
63.
European Medicine Agency (2018) EMA’s final opinion confirms restrictions on use of linear gadolinium agents in body scans. https://​www.​ema.​europa.​eu (Erstellt: 23. Nov. 2017). Zugegriffen: 6. Dez. 2018 (EMA/625317/2017)
64.
Taoka T, Naganawa S (2018) Gadolinium-based contrast media, cerebrospinal fluid and the Glymphatic system: possible mechanisms for the deposition of gadolinium in the brain. Magn Reson Med Sci 17(2):111–119PubMedPubMedCentralCrossRef
65.
Welk B, McArthur E, Morrow SA, MacDonald P, Hayward J, Leung A, Lum A (2016) Association between gadolinium contrast exposure and the risk of parkinsonism. JAMA 316(1):96–98PubMedCrossRef
66.
Cocozza S, Pontillo G, Lanzillo R, Russo C, Petracca M, Di SM, Paolella C, Vola EA, Criscuolo C, Moccia M, Lamberti A, Monti S, Brescia MV, Elefante A, Palma G, Tedeschi E, Brunetti A (2019) MRI features suggestive of gadolinium retention do not correlate with expanded disability status scale worsening in multiple sclerosis. Neuroradiology 61(2):155–162PubMedCrossRef
67.
McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Paolini MA, Murray DL, Williamson EE, Eckel LJ (2017) Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without Intracranial abnormalities. Radiology 285(2):546–554PubMedCrossRef
68.
McDonald RJ, McDonald JS, Dai D, Schroeder D, Jentoft ME, Murray DL, Kadirvel R, Eckel LJ, Kallmes DF (2017) Comparison of gadolinium concentrations within multiple rat organs after intravenous administration of linear versus Macrocyclic gadolinium chelates. Radiology 285(2):536–545PubMedCrossRef
69.
Forslin Y, Shams S, Hashim F, Aspelin P, Bergendal G, Martola J, Fredrikson S, Kristoffersen-Wiberg M, Granberg T (2017) Retention of gadolinium-based contrast agents in multiple sclerosis: retrospective analysis of an 18-year longitudinal study. Ajnr Am J Neuroradiol 38(7):1311–1316PubMedCrossRefPubMedCentral
70.
Semelka RC, Ramalho J, Vakharia A, AlObaidy M, Burke LM, Jay M, Ramalho M (2016) Gadolinium deposition disease: Initial description of a disease that has been around for a while. Magn Reson Imaging 34(10):1383–1390PubMedCrossRef
71.
72.
73.
Gathings RM, Reddy R, Santa CD, Brodell RT (2015) Gadolinium-associated plaques: a new, distinctive clinical entity. Jama Dermatol 151(3):316–319PubMedCrossRef
Metadaten
Titel
Gadoliniumablagerungen – Morbus Gadolinium
verfasst von
P. Raczeck
P. Fries
A. Bücker
G. Schneider
Publikationsdatum
08.04.2019
Verlag
Springer Medizin
Erschienen in
Die Radiologie / Ausgabe 5/2019
Print ISSN: 2731-7048
Elektronische ISSN: 2731-7056
DOI
https://doi.org/10.1007/s00117-019-0522-9

Weitere Artikel der Ausgabe 5/2019

Die Radiologie 5/2019 Zur Ausgabe

Leitthema

Kontrastmittel: Handlungsempfehlungen für die Praxis

Leitthema

Pharmakokinetik von gadoliniumhaltigen Kontrastmitteln

Leitthema

Jodhaltige Kontrastmittel bei Patienten mit Schilddrüsenerkrankungen

Einführung zum Thema

Kontrastprogramm

Leitthema

Nierenfunktion bei kontrastmittelverstärkter Bildgebung

In eigener Sache

Erklärung zu finanziellen und nichtfinanziellen Interessen in CME-Fortbildungen von Springer Medizin

Passend zum Thema

ANZEIGE
Anaphylaxie

Es wäre so einfach, ein Leben zu retten – Wenn man nur daran denkt…

Anaphylaxie ist eine akute schwere allergische Reaktion und somit die schwerste Komplikation in der Allergologie. Darauf sollten Ärztinnen und Ärzte vorbereitet sein.

Bildnachweise